Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer
| Autor: | Sobuhi Iqbal, N.K. Shukla, Suryanarayana S.V. Deo, Surabhi Sharma, Ajay Gogia, Vinod Raina, Sreenivas Vishnubhatla, Sandeep Mathur |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Dna integrity
medicine.medical_specialty Univariate analysis Multidisciplinary Tumor size Research Circulating cell-free DNA Disease Biology Bioinformatics medicine.disease Gastroenterology Circulating Cell-Free DNA Breast cancer Real-time polymerase chain reaction Internal medicine medicine DNA integrity Surgery Serum dna |
| Zdroj: | SpringerPlus |
| ISSN: | 2193-1801 |
| DOI: | 10.1186/s40064-015-1071-y |
| Popis: | The aim of our study was to look for alternative predictive biomarkers for breast cancer management in limited resource setup. A comprehensive analysis of circulating cell-free DNA (CCFD) in serum at baseline was performed to assess its prognostic potential. Quantitative polymerase chain reaction (qPCR) of ALU sequences using ALU115 and ALU247 primers was carried out in patients (N: baseline 148, postoperative 47) and 51 healthy controls. Mean serum DNA integrity, levels of ALU 247 and levels of ALU 115 were significantly higher in patients than in healthy females. No significant differences were observed in the levels ALU 247 and ALU 115 between stage IV and earlier stages of the disease. The DNA integrity was significantly higher in stage IV than earlier stages. A significant decrease in DNA integrity was observed after surgery (pre: 0.55 ± 0.23 vs post: 0.43 ± 0.30; P = 0.002) while no such change could be observed for ALU 247 and ALU 115. Baseline DNA integrity was significantly higher in relapsed patients than in patients who were free of disease (P = 0.005). Higher baseline DNA integrity was also indicated, though statistically not significant, in patients who died (P = 0.14). In contrast, ALU 247 and ALU 115 levels were decreased in died patients as compared to survivors (24.8 ± 34.80 vs 73.5 ± 170.83, P = 0.02 for ALU 247 and 41.0 ± 47.99 vs 159.5 ± 299.54, P = 0.005 for ALU 115). Baseline levels of ALU 115 and ALU 247 were lower in relapsed patients, though statistically not significant. In univariate analysis, the only clinic-pathological parameter associated with disease prognosis was tumor size. The hazards of 5-year overall mortality was 3.60 (95 % CI: 1.03 12.53, P = 0.03) among patients with lower baseline serum levels of CCFD (ALU 247 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|